Transnasal Endoscopic Injection of Botulinum Toxin in Patients with Adductor Spasmodic Dysphonia

Document Type : Original

Authors

1 Department of Otorhinolaryngology – Head and Neck Surgery, American University of Beirut Medical Center, Beirut, Lebanon.

2 Faculty of Medicine, American University of Beirut, Beirut, Lebanon.

10.22038/ijorl.2024.76713.3569

Abstract

Introduction:
Adductor Spasmodic Dysphonia (ADSD) is the most common form of spasmodic dysphonia. It encompasses various symptoms affecting voice and speech. The objective of this study is to report the management of patients with ADSD using the transnasal endoscopic approach for laryngeal Botulinum Toxin (Botox) injection.
Materials and Methods:
A retrospective chart review of patients with ADSD who underwent transnasal endoscopic laryngeal Botox injection was conducted. Voice outcome measures included the Voice Handicap Index-10 (VHI-10) score and the degree of speech fluency.
Results:
Eight patients with ADSD who underwent 20 office-based transnasal endoscopic laryngeal Botox injections were included. The most commonly injected sites were the thyroarytenoid muscle (TA) and the false vocal fold in 95% and 55% of the cases, respectively. The mean dose of injected Botox was 2.48 ± 0.55 IU in the TA muscle, and 2.14 ± 0.53 IU in the false vocal fold. The mean amount of Botox injected in the larynx was 7.16 ± 2.42 IU. The mean follow-up period was 17.7 ± 13.3 months. There was marked improvement in speech fluency in 64.7% of the cases and mild improvement in one third of the cases. Marked improvement in speech fluency was recorded in 64.7% of the cases and mild improvement in one third of the cases. The mean VHI-10 score of patients dropped significantly from 22.47±4.08 to 15±4.69 following treatment (p<0.001).
Conclusions:
The transnasal endoscopic approach is an effective and well-tolerated approach for laryngeal Botox injection in patients with ADSD.

Keywords

Main Subjects

References

  1. Hintze JM, Ludlow CL, Bansberg SF, Adler CH, Lott DG. Spasmodic Dysphonia: A Review. Part 1: Pathogenic Factors. Otolaryngol Head Neck Surg. 2017;157(4):551-557. doi: 10.1177/019459981772 85 21
  2. Hintze JM, Ludlow CL, Bansberg SF, Adler CH, Lott DG. Spasmodic Dysphonia: A Review. Part 2: Characterization of Pathophysiology. Otolaryngol Head Neck Surg. 2017;157(4):558-564. doi:10. 1177/0194599817728465
  3. Klein C, Brin MF, de Leon D, et al. De novo mutations (GAG deletion) in the DYT1 gene in two non-Jewish patients with early-onset dystonia. Hum Mol Genet. 1998;7(7):1133-1136. doi:10.1093/ hmg/7.7.1133
  4. Tisch SH, Brake HM, Law M, Cole IE, Darveniza P. Spasmodic dysphonia: clinical features and effects of botulinum toxin therapy in 169 patients-an Australian experience. J Clin Neurosci. 2003; 10(4):434-8. doi:10.1016/s0967-5868(03) 00020-1.
  5. Patel AB, Bansberg SF, Adler CH, Lott DG, Crujido L. The Mayo Clinic Arizona Spasmodic Dysphonia Experience: A Demographic Analysis of 718 Patients. Ann Otol Rhinol Laryngol. 2015; 124(11):859-863. doi:10.1177/0003489415588557 Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope. 1998;108:1435-1441. doi: 10.1097/00005537-199810000-00003
  6. Kostic VS, Agosta F, Sarro L, et al. Brain structural changes in spasmodic dysphonia: A multimodal magnetic resonance imaging study. Parkinsonism Relat Disord. 2016; 25:78-84. doi: 10.1016/j.parkreldis.2016.02.003
  7. Kiyuna A, Kise N, Hiratsuka M, et al. Brain Activity in Patients with Adductor Spasmodic Dysphonia Detected by Functional Magnetic Resonance Imaging. J Voice. 2017;31(3):379.e1-379.e11. doi:10.1016/j.jvoice.2016.09.018. 
  8. Patel PN, Kabagambe EK, Starkweather JC, et al. Outcomes of Onabotulinum Toxin A Treatment for Adductor Spasmodic Dysphonia and Laryngeal Tremor. JAMA Otolaryngol Head Neck Surg. 2018;144(4):293-299. doi:10. 1001/jamaoto.2017.3088
  9. van Esch BF, Wegner I, Stegeman I, Grolman W. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients. Otolaryngol Head Neck Surg. 2017;156(2): 238-254. doi: 10.1177/0194599816675320
  10. Rhew K, Fiedler DA, Ludlow CL. Technique for injection of botulinum toxin through the flexible nasolaryngoscope. Otolaryngol Head Neck Surg. 1994;111(6):787-794. doi:10.1177/0194599894111 00615
  11. Hussain A, Thiel G, Shakeel M. Trans-nasal injection of botulinum toxin. J Laryngol Otol. 2009; 123(7):783-785. doi:10.1017/S0022215109004782
  12. Kaderbay A, Righini CA, Castellanos PF, Atallah I. Office-based endoscopic botulinum toxin injection in laryngeal movement disorders. Eur Ann Otorhinolaryngol Head Neck Dis. 2018;135(3):205-207. doi: 10.1016/j.anorl.2018.01.007
  13. Rosen CA, Lee AS, Osborne J, Zullo T, Murry T. Development and validation of the voice handicap index-10. Laryngoscope. 2004; 114(9): 1549-1556. doi: 10.1097/00005537-200409000-00009
  14. Blitzer A, Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope. 2001;111(2):218-226. doi:10.1097/ 00005537-200102000-00006
  15. Sataloff RT, Mandel S, Mann EA, Ludlow CL; AAEM Laryngeal Task Force. Laryngeal electromyography: an evidence-based review. Muscle Nerve. 2003;28(6): 767-772.doi :10. 1002/ mus. 10503
  16. Green DC, Berke GS, Ward PH, Gerratt BR. Point-touch technique of botulinum toxin injection for the treatment of spasmodic dysphonia. Ann Otol Rhinol Laryngol. 1992;101(11):883-887. doi:10. 1177/000348949210101101

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1. Kim JW, Park JH, Park KN, Lee SW. Treatment efficacy of electromyography versus fiberscopy-guided botulinum toxin injection in adductor spasmodic dysphonia patients: a prospective comparative study. ScientificWorldJournal. 2014; 2014:327928. doi:10.1155/2014/327928
  2. Ford CN, Bless DM, Lowery JD. Indirect laryngoscopic approach for injection of botulinum toxin in spasmodic dysphonia. Otolaryngol Head Neck Surg. 1990;103(5(Pt1)):752-758. doi: 10.1177/ 0194 599 89010300515
  3. Rosen M, Malmgren LT, Gacek RR. Three-dimensional computer reconstruction of the distribution of neuromuscular junctions in the thyroarytenoid muscle. Ann Otol Rhinol Laryngol. 1983;92(5Pt1):424-429. doi:10.1177/000348948309200 503
  4. Inagi K, Ford CN, Bless DM, Heisey D. Analysis of factors affecting botulinum toxin results in spasmodic dysphonia. J Voice. 1996;10(3):306-313. doi:10.1016/s0892-1997(96)80012-9
Iranian Journal of Otorhinolaryngology
Volume 36, Issue 5
September and October 2024
Pages 595-601

Files

Share

How to cite

Statistics